CN105125625A - Composition with hypolipidemic effect - Google Patents
Composition with hypolipidemic effect Download PDFInfo
- Publication number
- CN105125625A CN105125625A CN201510559938.1A CN201510559938A CN105125625A CN 105125625 A CN105125625 A CN 105125625A CN 201510559938 A CN201510559938 A CN 201510559938A CN 105125625 A CN105125625 A CN 105125625A
- Authority
- CN
- China
- Prior art keywords
- group
- concentrated solution
- present
- dose group
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition with a hypolipidemic effect. The composition is prepared from the following components in parts by weight: 20-50 parts of cortex albiziae, 32-45 parts of lithospermum, 16-25 parts of elecampane, 8-15 parts of trogopterus dung, and 10-20 parts of caulis spatholobi. The composition is prepared from the natural traditional Chinese medicinal materials, and has the hypolipidemic effect.
Description
Technical field
The present invention relates to a kind of compositions with effect for reducing blood fat, belong to medicines and health protection technical field.
Background technology
In recent years, along with the raising of people's living standard, people improve constantly for the absorption level of Protein in Food and fat, in mid-aged population and city white collar crowd, the phenomenon of Hyperlipidemia is comparatively general, and also presenting the trend of rejuvenation in recent years, its main cause may be: on the one hand, the improvement of quality of life, absorption fat content increases, and unsound dietary habit causes blood in human body in fat composition to change; On the other hand, live and work pressure is large, abnormal work and rest custom, and cause adolescence's body constitution to decline, capacity of self-regulation also reduces, and particularly the satisfy colony of adolescence of inequality of breakfast skipping and famine easily occurs hyperlipidemic conditions.Hyperlipidemic conditions can't directly cause the health of people at once to occur disease as a kind of chronic disease, and along with the increase of time, hyperlipidemic conditions can cause the contour risk diseases of cardiovascular and cerebrovascular disease.
The treatment of current hyperlipemia is mainly based on Statins, but statins easily causes the side effect such as myalgia, myopathy, rhabdomyolysis, needs emphasis to monitor blood fat and safety indexes.
At the field of Chinese medicines, many research shows Chinese medicine preventing and treating in hyperlipemia and has very large potentiality and superiority, and Chinese medicine contains multicomponent, Mutiple Targets due to it, in treatment hyperlipemia, have unique advantage.If simple Chinese medicine effectively can control hyperlipidaemic conditions, can avoid the toxic and side effects of Western medicine, greatly strengthen the compliance of patient consumes, thus be long-term treatment hyperlipemia disease, this is the developing direction of Chinese medicine hyperlipemia.
Summary of the invention
The object of the present invention is to provide a kind of compositions with effect for reducing blood fat, to solve the problem proposed in above-mentioned background technology.
For achieving the above object, the invention provides following technical scheme:
Have a compositions for effect for reducing blood fat, described compositions comprises: Cortex Albiziae 20-50 part, Radix Arnebiae (Radix Lithospermi) 32-45 part, Radix Aucklandiae 16-25 part, Oletum Trogopterori 8-15 part, Caulis Spatholobi 10-20 part.
Preferably: described a kind of compositions with effect for reducing blood fat, described compositions comprises: Cortex Albiziae 30-40 part, Radix Arnebiae (Radix Lithospermi) 35-42 part, Radix Aucklandiae 18-20 part, Oletum Trogopterori 8-13 part, Caulis Spatholobi 10-15 part.
Further preferably: described a kind of compositions with effect for reducing blood fat, described compositions comprises: Cortex Albiziae 30 parts, Radix Arnebiae (Radix Lithospermi) 35 parts, the Radix Aucklandiae 18 parts, Oletum Trogopterori 8 parts, Caulis Spatholobi 10 parts.
Still more preferably: described a kind of compositions with effect for reducing blood fat has effect for reducing blood fat.
The property of medicine and effect of Chinese crude drug of the present invention are as follows:
Cortex Albiziae is the dry bark of leguminous plant Herba Albiziae, and property is put down, and sweet in the mouth, GUIXIN, liver, lung meridian, have effect of resolving stagnation for tranquilization, promoting blood circulation and detumescence.For irritability, melancholy insomnia, lung abscess skin ulcer swells, and falls and flutters the pain of injury.
Radix Arnebiae (Radix Lithospermi) is the dry root of comfrey lithospermum euchromum Royle, Radix Arnebiae (Radix Lithospermi) or arnebia guttata Bunge, cold in nature, sweet in the mouth, salty, GUIXIN, Liver Channel, has removing heat from blood, invigorates blood circulation, effect of rash of detoxifying.Contain for heat in blood poison, macule purple is black, measles without adequate eruption, skin infection, eczema, burn due to hot liquid or fire.
The Radix Aucklandiae is the dry root of the feverfew Radix Aucklandiae, warm in nature, acrid in the mouth, hardship, returns spleen, stomach, large intestine, three burnt, gallbladder meridians, has effect of promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion.For breast gastral cavity distending pain, heavy after dysentery, food stagnation does not disappear, anorexia.
Oletum Trogopterori, be flying squirrel section animal trogopterus xanthipes or the dry feces flying the little flying squirrel of murine, warm in nature, sweet in the mouth, returns liver, spleen channel, has effect of promoting blood circulation to remove blood stasis, parch to black hemostasis.Have a pain for trusted subordinate's congestion, dysmenorrhea, blood stasis amenorrhea, puerperal abdominalgia with blood stasis; Parch to black controls metrostaxis; Traumatic injury is controlled in external, Serpentis, insect bite wound.
Caulis Spatholobi is the dry rattan of leguminous plant spatholobus suberectus, warm in nature, bitter in the mouth, sweet, returns liver, kidney channel, have enrich blood, invigorate blood circulation, effect of dredging collateral.For menoxenia, blood deficiency and yellow complexion, paralysis and numbness, rheumatic arthralgia.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention with have resolving stagnation for tranquilization, promoting blood circulation and detumescence effect Cortex Albiziae for monarch drug, with removing heat from blood and promoting blood circulation, removing toxic substances rash Radix Arnebiae (Radix Lithospermi), the Radix Aucklandiae of promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion is ministerial drug; With the Oletum Trogopterori of promoting blood circulation to remove blood stasis, hemostasis for adjuvant drug, with the Caulis Spatholobi of promoting blood circulation to remove obstruction in the collateral for making medicine, all medicines share, play altogether invigorate blood circulation, subside a swelling, dredge the meridian passage, promoting the circulation of QI to relieve pain, blood fat reducing effect, be applicable to treatment and the control of hyperlipidemia.
The present invention be rat suppository is formed by pharmaceutical composition impact, on the impact of clotting time of mice, the impact on the mice bleeding time, on the impact of mice oxygen deficit tolerance and the impact on mice serum triglyceride and cholesterol level situation, checking pharmaceutical composition is to the effect reducing hyperlipidemia.
Result of study shows: pharmaceutical composition can reduce the formation of rat vein bypass thrombosis, can reduce the formation of cerebral thrombosis; Pharmaceutical composition extends mice blood coagulation and mice hemorrhage required time; The hypoxia mice time-to-live can be extended under anaerobic condition; Mice serum triglyceride and cholesterol level can be reduced.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
Compositions: Cortex Albiziae 20g, Radix Arnebiae (Radix Lithospermi) 32g, Radix Aucklandiae 16g, Oletum Trogopterori 8g, Caulis Spatholobi 10g.
Embodiment 2
Compositions: Cortex Albiziae 50g, Radix Arnebiae (Radix Lithospermi) 45g, Radix Aucklandiae 25g, Oletum Trogopterori 15g, Caulis Spatholobi 20g.
Embodiment 3
Compositions: Cortex Albiziae 26g, Radix Arnebiae (Radix Lithospermi) 37g, Radix Aucklandiae 19g, Oletum Trogopterori 10g, Caulis Spatholobi 17g.
Embodiment 4
Compositions: Cortex Albiziae 30g, Radix Arnebiae (Radix Lithospermi) 35g, Radix Aucklandiae 18g, Oletum Trogopterori 8g, Caulis Spatholobi 10g.
Embodiment 5
Pharmacological experiment
By the compositions of the embodiment of the present invention 4, carry out extracts active ingredients, specific as follows: (1) extracts: take Cortex Albiziae 30g, Radix Arnebiae (Radix Lithospermi) 35g, Radix Aucklandiae 18g, Caulis Spatholobi 10g, mix homogeneously, add 1000ml purified water, decoct 2 hours, obtain decoction liquor 1; (2) alcohol extraction: take Oletum Trogopterori 8g in proportion, putting into dehydrator, to choose temperature be 80 degree, dry 3 hours.Be ground into coarse powder after oven dry, add 300ml75% ethanol, extract 3 hours; Reclaim ethanol, obtain concentrated solution 2; (3) concentrated: concentrated solution 1, concentrated solution 2 mix, leave standstill, filter, simmer down to 100ml solution.
Adopt the impact that the obtained concentrated solution of artery-vein the method for bypass detection embodiment of the present invention 4 is formed rat suppository; Cerebral thrombosis method is adopted to detect the obtained concentrated solution of the embodiment of the present invention 4 to the thrombotic impact of mouse brain; Capillary glass tube method is adopted to detect the obtained concentrated solution of the embodiment of the present invention 4 to the impact of clotting time of mice; Adopt and cut the obtained concentrated solution of the tail method detection embodiment of the present invention 4 to the impact in mice bleeding time; Non-pressure process is adopted to detect the obtained concentrated solution of the embodiment of the present invention 4 to the impact of mice oxygen deficit tolerance; Measure mice serum triglyceride content and cholesterol level, carry out especially by following experiment:
1 experiment material
1.1 laboratory animal
Wistar rat and Kun Ming mice, respectively at 18 ~ 24 DEG C, in the environment of relative humidity 50 ~ 60%, free drinking water diet, male and female divide cage.
1.2 experiment reagent
Triglyceride detection kit, cholesterin detection reagent box.
1.3 experimental apparatus and equipment
22R low temperature supercentrifuge, 722 visible spectrophotometers, DY89-1 tissue refiner, DPX-9162B-1 electro-heating standing-temperature cultivator, electronic balance, microplate reader, washes trigger, superclean bench, analytical balance, stopwatch.
2 experimental techniques
2.1 rat artery-vein the method for bypass detect the obtained concentrated solution of the embodiment of the present invention 4 to thrombotic impact.
Get Wistar rat 80, body weight 200 ~ 300g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, middle dosage group 30ml/kg, high dose group 50ml/kg; Continuous gavage 15 days.After last administration 40 minutes, lumbar injection urethane 1g/g, finally be separated Rat Right common carotid artery and left external jugular vein, be full of polyethylene tube with 50u/ml heparin-saline liquid, interrupt putting into the long trumpeter's art silk thread of one section of 5cm in advance, left jugular vein and right common carotid artery are successively inserted in pipe two ends, open bulldog clamp immediately, make blood flow logical 10 minutes, rear middle Herba Clinopodii, take out silk thread and claim wet weight of thrombus.
The concentrated solution that 2.2 embodiment of the present invention 3 obtain is on the impact of mice on cerebral thrombosis.
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, middle dosage group 30ml/kg, high dose group 50ml/kg; Successive administration 15 days.After last administration, 1 hour each tail vein injection collagen protein-epinephrine solution 0.3ml/ only, observes hemiplegia animal in 15 minutes and recover number.
2.3 capillary glass tube methods survey clotting time of mice.
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 3 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, and middle dosage group 30ml/kg, high dose group 50ml/kg, be administered once.Administration, after 1 hour, by muscle choroid plexus after capillary glass tube insertion mice ophthalmic corner of the eyes ball, is 4 ~ 5mm deeply, rotates gently and retract.Start timing in autoblood inflow pipe, blood fills rear taking-up capillary glass tube and lies against on table, and the two ends capillary tube that fractureed every 30 seconds is about 0.5cm, and slowly pull open to the left and right, whether the observation place of fractureing has blood clotting silk, and till there is blood clotting silk, institute's elapsed-time standards is clotting time.
2.4 cut tail method surveys the mice bleeding time:
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, and middle dosage group 30ml/kg, high dose group 50ml/kg, be administered once.Administration, after 1 hour, respectively in order to cutting cross-section for Mouse Tail-tip 1 ~ 2mm place, treats that blood overflows beginning timing voluntarily, and drew drop of blood once every 30 seconds, till blood stops naturally, institute's elapsed-time standards is the bleeding time.
2.5 oxygen deficit tolerance experiments
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, middle dosage group 30ml/kg, high dose group 50ml/kg; Be administered once.Administration is after 1 hour, and bottom mice being put into 250ml is covered with the port grinding bottle of sodica calx, records each mice anoxia enduring conditional survivor time.
The mensuration of 2.6 mice serum triglyceride content
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, middle dosage group 30ml/kg, high dose group 50ml/kg; Meanwhile, conventionally feed the higher fatty acid and special feedstuff of hypercholesterolemia, continuous 15 days, after 15 days, survey serum levels of triglyceride content by micromethod.
The mensuration of 2.7 mice serum cholesterol levels
Get Kunming mouse 80, body weight is 20 ± 2g, male and female half and half, be divided into 4 groups at random, often organize 20, be respectively the concentrated solution high dose group that dosage group in the obtained concentrated solution of the obtained concentrated solution low dose group of blank group, the embodiment of the present invention 4, the embodiment of the present invention 4, the embodiment of the present invention 4 are obtained.Blank group gives normal saline 15ml/kg, and the other gavage of all the other three components gives the embodiment of the present invention 4 obtained concentrated solution, and dosage is low dose group 10.5ml/kg, middle dosage group 30ml/kg, high dose group 50ml/kg; Meanwhile, conventionally feed the higher fatty acid and special feedstuff of hypercholesterolemia, continuous 21 days, after 21 days, survey serum cholesterol content by micromethod.
2.8 statistical method
Data acquisition mean ± standard deviation represents, compare between group and adopt t inspection, P < 0.05 has statistical significance for difference.
3 experimental results
Table 1 rat artery-vein the method for bypass detects the obtained concentrated solution of the embodiment of the present invention 4 to thrombotic impact
| Group | Number of cases/only | Thrombus weight (mg) |
| Blank group | 20 | 16.58±4.23 |
| Low dose group | 20 | 11.08±1.95** |
| Middle dosage group | 20 | 9.38±1.85** |
| High dose group | 20 | 5.45±0.52** |
Note: compare with model group,
*p < 0.05;
Result is as shown in table 1, shown by table 1 experimental result, the concentrated solution low dose group that the embodiment of the present invention 4 obtains, middle dosage group, high dose group compare with the thrombus weight of blank group, have notable difference, have statistical significance (P < 0.05).
The concentrated solution that table 2 embodiment of the present invention 4 obtains is on the impact (mouse brain thrombosis experiment) of mice on cerebral thrombosis
| Group | Number of cases/only | Number/is only recovered in 15 minutes | Recover in 15 minutes | X2 |
| Blank group | 20 | 0 | 0％ | - |
| Low dose group | 20 | 7 | 35％ | 4.25 |
| Middle dosage group | 20 | 13 | 65％ | 9.08 |
| High dose group | 20 | 17 | 85％ | 14.55 |
Result is as shown in table 2, checked through statistics X2 by table 2 experimental result, the obtained concentrated solution low dose group of the embodiment of the present invention 4, middle dosage group, high dose group compared with blank group, the equal tool statistical significance of difference (P < 0.05) between group.
The concentrated solution that table 3 embodiment of the present invention 4 obtains is on the impact (capillary glass tube method) of clotting time of mice
| Group | Number of cases/only | Clotting time (second) |
| Blank group | 20 | 4.15±2.23 |
| Low dose group | 20 | 4.65±0.95 |
| Middle dosage group | 20 | 5.38±1.85** |
| High dose group | 20 | 5.45±2.52** |
Note: compared with blank group,
*p < 0.05.
Result is as shown in table 3, and from table 3, the concentrated solution low dose group that the embodiment of the present invention 4 obtains, middle dosage group, high dose group are compared with blank group, and difference all has significant (P < 0.05).
The concentrated solution that table 4 embodiment of the present invention 4 obtains is on the impact (cutting tail method) in mice bleeding time
| Group | Number of cases/only | Bleeding time (second) |
| Blank group | 20 | 1.18±0.23 |
| Low dose group | 20 | 1.35±0.15 |
| Middle dosage group | 20 | 1.32±0.25 |
| High dose group | 20 | 1.39±0.22 |
Note: compared with blank group,
*p < 0.05.
Result is as shown in table 4, and from table 4, the concentrated solution low dose group that the embodiment of the present invention 4 obtains, middle dosage group, high dose group are compared with blank group, and difference all has significance justice (P < 0.05).
The concentrated solution that table 5 embodiment of the present invention 4 obtains is on the impact of mouse survival time
| Group | Number of cases/only | Time-to-live (second) |
| Blank group | 20 | 31.56±3.23 |
| Low dose group | 20 | 35.35±3.18 |
| Middle dosage group | 20 | 39.28±5.29 |
| High dose group | 20 | 41.39±9.50 |
Note: compared with blank group,
*p < 0.05.
Result is as shown in table 5, and from table 5, the concentrated solution low dose group that the embodiment of the present invention 4 obtains, middle dosage group, high dose group are compared with blank group, and difference all has significant (P < 0.05).
The obtained concentrated solution of table 6 embodiment of the present invention 4 is on the impact of serum levels of triglyceride and cholesterol level
| Group | Number of cases/only | Triglyceride (mmol/L) | T-CHOL (mmol/L) |
| Blank group | 20 | 2.56±0.30 | 6.45±0.13 |
| Low dose group | 20 | 2.28±0.12 | 6.08±0.82 |
| Middle dosage group | 20 | 1.93±0.14 | 5.65±0.88 |
| High dose group | 20 | 1.67.±0.09 | 5.23±0.45 |
Note: compared with blank group, * P < 0.01; Compared with model group, * * P < 0.05.
Result is as shown in table 6, and from table 6, the concentrated solution low dose group that the embodiment of the present invention 4 obtains, middle dosage group, high dose group are compared with model group, and difference all has significant (P<0.05).
Claims (4)
1. have a compositions for effect for reducing blood fat, it is characterized in that, described compositions comprises: Cortex Albiziae 20-50 part, Radix Arnebiae (Radix Lithospermi) 32-45 part, Radix Aucklandiae 16-25 part, Oletum Trogopterori 8-15 part, Caulis Spatholobi 10-20 part.
2. a kind of compositions with effect for reducing blood fat according to claim 1, it is characterized in that, described compositions comprises: Cortex Albiziae 30-40 part, Radix Arnebiae (Radix Lithospermi) 35-42 part, Radix Aucklandiae 18-20 part, Oletum Trogopterori 8-13 part, Caulis Spatholobi 10-15 part.
3. a kind of compositions with effect for reducing blood fat according to claim 2, is characterized in that, described compositions comprises: Cortex Albiziae 30 parts, Radix Arnebiae (Radix Lithospermi) 35 parts, the Radix Aucklandiae 18 parts, Oletum Trogopterori 8 parts, Caulis Spatholobi 10 parts.
4., according to the arbitrary described a kind of compositions with effect for reducing blood fat of claim 1-3, it is characterized in that there is effect for reducing blood fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559938.1A CN105125625A (en) | 2015-09-03 | 2015-09-03 | Composition with hypolipidemic effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559938.1A CN105125625A (en) | 2015-09-03 | 2015-09-03 | Composition with hypolipidemic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125625A true CN105125625A (en) | 2015-12-09 |
Family
ID=54711447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510559938.1A Pending CN105125625A (en) | 2015-09-03 | 2015-09-03 | Composition with hypolipidemic effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125625A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939435A (en) * | 2006-09-27 | 2007-04-04 | 杭州民生药业集团有限公司 | Hypolipidemic composition and its use |
| CN101264091A (en) * | 2007-03-15 | 2008-09-17 | 吴林根 | Blood-fat reducing composition and uses thereof |
| CN101757470A (en) * | 2008-12-25 | 2010-06-30 | 中国科学院成都生物研究所 | Blood fat lowering composition |
| CN103463426A (en) * | 2013-09-03 | 2013-12-25 | 陈柏林 | Traditional Chinese medicine pill for treating hyperlipidemia |
| CN104225466A (en) * | 2014-09-04 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicinal composition used for lowering blood lipid |
-
2015
- 2015-09-03 CN CN201510559938.1A patent/CN105125625A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939435A (en) * | 2006-09-27 | 2007-04-04 | 杭州民生药业集团有限公司 | Hypolipidemic composition and its use |
| CN101264091A (en) * | 2007-03-15 | 2008-09-17 | 吴林根 | Blood-fat reducing composition and uses thereof |
| CN101757470A (en) * | 2008-12-25 | 2010-06-30 | 中国科学院成都生物研究所 | Blood fat lowering composition |
| CN103463426A (en) * | 2013-09-03 | 2013-12-25 | 陈柏林 | Traditional Chinese medicine pill for treating hyperlipidemia |
| CN104225466A (en) * | 2014-09-04 | 2014-12-24 | 上海焦点生物技术有限公司 | Traditional Chinese medicinal composition used for lowering blood lipid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108653332A (en) | Inhibition thrombosis and platelet aggregation and the bear gall powder and purposes for preventing cerebral ischemia | |
| CN104435169A (en) | Traditional Chinese medicine combination for treating bone injury and fracture and preparation method of traditional Chinese medicine combination | |
| CN103990079A (en) | Pharmaceutical composition for treating Qi-stagnation and blood stasis type lumbar muscle strain and preparation method of pharmaceutical composition | |
| CN106420949A (en) | Blood-activating analgesic ointment and preparation method thereof | |
| CN105362785A (en) | Medicine composition for treating primary hypertension and preparation method thereof | |
| CN104840623A (en) | Traditional Chinese medicine combination for treating toxic heat flourishing type burn and preparation method thereof | |
| CN105125625A (en) | Composition with hypolipidemic effect | |
| CN105381004A (en) | Health product with blood fat reducing effect, and preparation method and use thereof | |
| CN107095922A (en) | Children's removing jaundice precious jade medicine bath foam and preparation method thereof | |
| CN103028046B (en) | Traditional Chinese medicine composition for treating atrophic rhinitis and preparation method of traditional Chinese medicine composition | |
| CN105233152A (en) | Traditional Chinese medicinal composition having function of relieving pain and preparation method of traditional Chinese medicinal composition | |
| CN105288493A (en) | Method for preparing traditional Chinese medicine preparation capable of treating schizophrenia | |
| CN104971271A (en) | Medicine for treating benign prostatic hyperplasia due to damp-retained heat and preparation method thereof | |
| CN105943700B (en) | The Chinese medicine composition and its preparation method and application of numbness is led in a kind of kidney tonifying | |
| CN110960618B (en) | Preparation method of composition for joint protection | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN108310169A (en) | Pharmaceutical composition and preparation method thereof for preventing osteoarthritis | |
| CN103989969A (en) | Traditional Chinese medicament for treating wind-cold obstruction type cervical spondylotic radiculopathy and preparation method thereof | |
| CN112439016B (en) | Traditional Chinese medicine composition for treating acute soft tissue injury, preparation method and application | |
| CN105250512A (en) | Traditional Chinese medicine ointment for treating abdominal incision induration after cesarean operation | |
| CN106063802A (en) | Cacumen Myricariae Germanicae effective site, Its Preparation Method And Use | |
| CN105125781A (en) | Traditional Chinese medicine gel for treating stage-III pressure sore and preparing method of traditional Chinese medicine gel | |
| CN105456565A (en) | Traditional Chinese medicine preparation for treating hepatitis A and preparation method thereof | |
| CN104971315A (en) | Antibacterial gel for treating injury wound infection and preparation method of antibacterial gel | |
| CN114632103A (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151209 |